Bayer Championing Advancements in Radiology Pipeline and Accelerating AI Innovation
Comprehensive program focused on innovation in AI – hosted jointly by teams from Calantic Digital Solutions and Blackford Analysis
Stay updated with breaking news from Finding Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Comprehensive program focused on innovation in AI – hosted jointly by teams from Calantic Digital Solutions and Blackford Analysis
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib
Bracco's attendance at RSNA follows FDA approval of Gadopiclenol injection, a novel macrocyclic high-relaxivity gadolinium-based contrast agent wh...
Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA). The introduction of VUEWAY injection is the result of a strategic, global collaboration between Bracco and Guerbet in both research, development, and manufacturing of the product signed in December 2021.